Differentiating PD-1+ stem-like CD8 T cells towards distinct effectors with enhanced therapeutic potential by an engineered IL-2 cis-targeted to PD-1

Pablo Umaña(Roche (Switzerland)), Volker Teichgräber(Roche (Switzerland))

Research Square

March 17, 2021

10.21203/rs.3.rs-329812/v1

Cited by 5

Related Papers

PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells

|Nature|2022|257

Fibroblast Activation Protein α-Targeted CD40 Agonism Abrogates Systemic Toxicity and Enables Administration of High Doses to Induce Effective Antitumor Immunity

|Clinical Cancer Research|2021|62

The tumor-targeted CD40 agonist CEA-CD40 promotes T cell priming via a dual mode of action by increasing antigen delivery to dendritic cells and enhancing their activation

|Journal for ImmunoTherapy of Cancer|2022|24